Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has reported promising interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab), a novel treatment for metastatic castration-resistant prostate cancer. The study, which involves the first-in-class CD105 antagonist, has shown no dose-limiting toxicities or unexpected adverse events in the initial cohort of ten patients, with no Grade 3 or 4 toxicities observed. This development is crucial as it underscores the potential of ENV-105 to be a safe and effective addition to the current treatment arsenal against prostate cancer, a disease that poses significant challenges due to its resistance to standard therapies.
The trial, currently enrolling 100 patients across prestigious institutions such as Cedars-Sinai, City of Hope, and Huntsman Cancer Center, combines ENV-105 with apalutamide, a standard hormone therapy. The interim efficacy data, anticipated in September 2025, could pave the way for a Phase 3 study, pending regulatory discussions. The significance of these findings lies in the drug's mechanism of action; ENV-105 targets CD105, a protein implicated in resistance to various cancer treatments. By inhibiting CD105, ENV-105 aims to overcome drug resistance and enhance the efficacy of standard therapies, offering hope to patients with limited treatment options.
This announcement is particularly important for the oncology community and patients worldwide, as metastatic castration-resistant prostate cancer remains a leading cause of cancer-related deaths among men. The positive safety profile of ENV-105 not only highlights its potential as a breakthrough therapy but also reinforces Kairos Pharma's commitment to addressing unmet medical needs in cancer treatment. For more information on the trial and Kairos Pharma's innovative approach to cancer therapy, visit https://ibn.fm/S1b3a.
